T1	PROC 107 110	DVd
#1	AnnotatorNotes T1	C4521443; Daratumumab/Bortezomib/Dexamethasone Regimen; Therapeutic or Preventive Procedure
T2	CHEM 67 78	Daratumumab
#2	AnnotatorNotes T2	C2346801; daratumumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 80 90	Bortezomib
#3	AnnotatorNotes T3	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T4	CHEM 93 105	dexametasona
#4	AnnotatorNotes T4	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T5	CHEM 121 131	Bortezomib
#5	AnnotatorNotes T5	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T6	CHEM 134 146	dexametasona
#6	AnnotatorNotes T6	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T7	DISO 167 194	mieloma múltiple en recaída
#7	AnnotatorNotes T7	C5577628; Relapsed/refractory multiple myeloma; Neoplastic Process
T8	PROC 231 244	Ensayo fase 3
#8	AnnotatorNotes T8	C0282461; Phase 3 Clinical Trial; Research Activity
T9	CHEM 259 270	Daratumumab
#9	AnnotatorNotes T9	C2346801; daratumumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	CHEM 272 282	Bortezomib
#10	AnnotatorNotes T10	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T11	CHEM 285 297	dexametasona
#11	AnnotatorNotes T11	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T12	CHEM 313 323	Bortezomib
#12	AnnotatorNotes T12	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T13	CHEM 326 338	dexametasona
#13	AnnotatorNotes T13	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T14	DISO 359 386	mieloma múltiple en recaída
#14	AnnotatorNotes T14	C5577628; Relapsed/refractory multiple myeloma; Neoplastic Process
T15	DISO 424 440	Mieloma Múltiple
#15	AnnotatorNotes T15	C0026764; Multiple Myeloma; Neoplastic Process
T16	DISO 492 508	mieloma múltiple
#16	AnnotatorNotes T16	C0026764; Multiple Myeloma; Neoplastic Process
T17	PROC 585 596	tratamiento
#17	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	DISO 605 621	mieloma múltiple
#18	AnnotatorNotes T18	C0026764; Multiple Myeloma; Neoplastic Process
T19	DISO 672 699	progresión de la enfermedad
#19	AnnotatorNotes T19	C0242656; Disease Progression; Pathologic Function
T20	CHEM 1067 1076	anti-CD38
#20	AnnotatorNotes T20	C4722395; Anti-CD38 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T21	PROC 1914 1928	procedimientos
#21	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T22	CHEM 1034 1045	daratumumab
#22	AnnotatorNotes T22	C2346801; daratumumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T23	PROC 1054 1076	tratamientos anti-CD38
T24	CHEM 1104 1111	VELCADE
#23	AnnotatorNotes T24	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T25	DISO 1142 1169	progresión de la enfermedad
#24	AnnotatorNotes T25	C0242656; Disease Progression; Pathologic Function
T26	CHEM 1197 1204	VELCADE
#25	AnnotatorNotes T26	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T27	CHEM 1271 1278	VELCADE
#26	AnnotatorNotes T27	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T28	CHEM 1311 1318	VELCADE
#27	AnnotatorNotes T28	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T29	CHEM 1357 1367	medicación
#28	AnnotatorNotes T29	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T30	DISO 1378 1400	acontecimiento adverso
#29	AnnotatorNotes T30	C0877248; Adverse event; Pathologic Function
T31	CHEM 1438 1445	VELCADE
#30	AnnotatorNotes T31	C1174739; Velcade; Organic Chemical · Pharmacologic Substance
T32	PROC 1472 1483	tratamiento
#31	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	DISO 1494 1501	mieloma
#32	AnnotatorNotes T33	C0026764; Multiple Myeloma; Neoplastic Process
T34	PROC 1560 1571	tratamiento
#33	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	PROC 1594 1608	aleatorización
#34	AnnotatorNotes T35	C0034656; Randomization; Research Activity
T36	DISO 1666 1683	neoplasia maligna
#35	AnnotatorNotes T36	C0006826; Malignant Neoplasms; Neoplastic Process
T37	DISO 1698 1714	mieloma múltiple
#36	AnnotatorNotes T37	C0026764; Multiple Myeloma; Neoplastic Process
T38	PROC 1755 1769	aleatorización
#37	AnnotatorNotes T38	C0034656; Randomization; Research Activity
T39	DISO 1816 1838	enfermedad concurrente
T40	DISO 1848 1867	infección sistémica
#38	AnnotatorNotes T40	C0243026; Sepsis; Disease or Syndrome
T41	PROC 148 150	Vd
#39	AnnotatorNotes T41	C1879895; Bortezomib-Dexamethasone Regimen; Therapeutic or Preventive Procedure
T42	DISO 701 703	PE
#40	AnnotatorNotes T42	C0242656; Disease Progression; Pathologic Function
T43	PROC 340 342	Vd
#41	AnnotatorNotes T43	C1879895; Bortezomib-Dexamethasone Regimen; Therapeutic or Preventive Procedure
T44	PROC 1344 1367	suspender la medicación
#42	AnnotatorNotes T44	C4288399; Pharmacotherapy Discontinuation; Therapeutic or Preventive Procedure
T45	PROC 767 774	régimen
#43	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T46	PROC 957 964	régimen
#44	AnnotatorNotes T46	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T47	PROC 1181 1192	tratamiento
#45	AnnotatorNotes T47	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T48	PROC 1255 1266	tratamiento
#46	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	PROC 1422 1433	tratamiento
#47	AnnotatorNotes T49	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T50	PROC 299 302	DVd
#48	AnnotatorNotes T50	C4521443; Daratumumab/Bortezomib/Dexamethasone Regimen; Therapeutic or Preventive Procedure
T51	Date 13 17	2014
T52	LIVB 155 162	sujetos
#49	AnnotatorNotes T52	C0681850; Study Subject; Group
T53	LIVB 347 354	sujetos
#50	AnnotatorNotes T53	C0681850; Study Subject; Group
T54	LIVB 472 478	sujeto
#51	AnnotatorNotes T54	C0681850; Study Subject; Group
T55	LIVB 527 533	sujeto
#52	AnnotatorNotes T55	C0681850; Study Subject; Group
T56	LIVB 628 634	sujeto
#53	AnnotatorNotes T56	C0681850; Study Subject; Group
T57	LIVB 782 788	sujeto
#54	AnnotatorNotes T57	C0681850; Study Subject; Group
T59	LIVB 865 871	sujeto
#55	AnnotatorNotes T59	C0681850; Study Subject; Group
T60	LIVB 1003 1009	sujeto
#56	AnnotatorNotes T60	C0681850; Study Subject; Group
T61	LIVB 1083 1089	sujeto
#57	AnnotatorNotes T61	C0681850; Study Subject; Group
T63	LIVB 1126 1132	sujeto
#58	AnnotatorNotes T63	C0681850; Study Subject; Group
T64	Duration 1210 1221	los 60 días
T65	LIVB 1287 1293	sujeto
#59	AnnotatorNotes T65	C0681850; Study Subject; Group
T66	LIVB 1453 1459	sujeto
#60	AnnotatorNotes T66	C0681850; Study Subject; Group
T67	Duration 1505 1520	las dos semanas
T68	Duration 1523 1555	cinco semividas farmacocinéticas
T69	PHYS 1539 1555	farmacocinéticas
#61	AnnotatorNotes T69	C0031327; Drug Kinetics; Physiologic Function
T70	LIVB 1637 1643	sujeto
#62	AnnotatorNotes T70	C0681850; Study Subject; Group
T71	Duration 1719 1732	los tres años
T72	LIVB 1776 1782	sujeto
#63	AnnotatorNotes T72	C0681850; Study Subject; Group
T58	DISO 1297 1308	intolerante
T62	PROC 821 837	estado funcional
#64	AnnotatorNotes T62	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T73	Neg_cue 1685 1697	distinta del
T74	Observation 1093 1101	responde
T75	Observation 911 928	respuesta parcial
A1	Assertion T37 Negated
A2	Status T17 History_of
A3	Status T46 History_of
A4	Status T22 History_of
A5	Status T23 History_of
A6	Status T20 History_of
A7	Status T30 History_of
A8	Status T36 History_of
A9	Status T34 History_of
A10	Status T58 History_of
#65	AnnotatorNotes T39	C1275743; Co-morbid conditions; Finding
#66	AnnotatorNotes T58	C0277585; Intolerance to drug; Pathologic Function
A11	Assertion T74 Negated
#67	AnnotatorNotes T74	C4055223; Clinical Response; Finding (?)
T76	Neg_cue 1090 1092	no
T77	Spec_cue 1883 1891	probable
T78	CONC 1896 1906	interfiera
A12	Assertion T78 Speculated
#68	AnnotatorNotes T78	C0521102; Interferes with; Functional Concept
R1	Negation Arg1:T76 Arg2:T74	
R2	Negation Arg1:T73 Arg2:T37	
R3	Speculation Arg1:T77 Arg2:T78	
T79	Observation 1799 1813	proceso médico
R4	Combined_with Arg1:T2 Arg2:T3	
R5	Combined_with Arg1:T3 Arg2:T4	
R6	Used_for Arg1:T2 Arg2:T1	
R7	Used_for Arg1:T5 Arg2:T41	
R8	Combined_with Arg1:T5 Arg2:T6	
R9	Experiences Arg1:T52 Arg2:T7	
R10	Experiences Arg1:T52 Arg2:T5	
R11	Experiences Arg1:T52 Arg2:T2	
T80	Quantifier_or_Qualifier 197 208	refractario
#69	AnnotatorNotes T80	C0205269; Unresponsive to Treatment; Functional Concept
R12	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T80	
T81	Quantifier_or_Qualifier 389 400	refractario
#70	AnnotatorNotes T81	C0205269; Unresponsive to Treatment; Functional Concept
R13	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T81	
R14	Combined_with Arg1:T9 Arg2:T10	
R15	Combined_with Arg1:T10 Arg2:T11	
R16	Used_for Arg1:T9 Arg2:T50	
R17	Combined_with Arg1:T12 Arg2:T13	
R18	Used_for Arg1:T12 Arg2:T43	
R19	Experiences Arg1:T53 Arg2:T12	
R20	Experiences Arg1:T53 Arg2:T9	
R21	Experiences Arg1:T53 Arg2:T14	
R22	Experiences Arg1:T54 Arg2:T16	
T82	Quantifier_or_Qualifier 556 574	al menos una línea
R23	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T82	
R24	Experiences Arg1:T55 Arg2:T17	
R25	Experiences Arg1:T55 Arg2:T18	
R26	Experiences Arg1:T56 Arg2:T19	
R27	Experiences Arg1:T56 Arg2:T42	
R28	Experiences Arg1:T56 Arg2:T45	
T83	CONC 842 846	ECOG
#71	AnnotatorNotes T83	C1520224; ECOG performance status; Intellectual Product
T84	Result_or_Value 850 858	0, 1 ó 2
R29	Has_Result_or_Value Arg1:T83 Arg2:T84	
R30	Used_for Arg1:T83 Arg2:T62	
R31	Experiences Arg1:T57 Arg2:T62	
R32	Experiences Arg1:T59 Arg2:T75	
R33	Experiences Arg1:T59 Arg2:T46	
T85	Quantifier_or_Qualifier 943 956	al menos a un
R34	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T85	
R35	Experiences Arg1:T60 Arg2:T22	
R36	Used_for Arg1:T20 Arg2:T23	
R37	Experiences Arg1:T60 Arg2:T23	
R38	Experiences Arg1:T61 Arg2:T74	
R39	Experiences Arg1:T61 Arg2:T24	
R40	Experiences Arg1:T63 Arg2:T25	
R41	Experiences Arg1:T63 Arg2:T24	
R42	Experiences Arg1:T63 Arg2:T74	
R43	Experiences Arg1:T63 Arg2:T47	
R44	Used_for Arg1:T26 Arg2:T47	
R46	Used_for Arg1:T27 Arg2:T48	
R47	Experiences Arg1:T61 Arg2:T25	
R48	Experiences Arg1:T61 Arg2:T48	
R49	Experiences Arg1:T65 Arg2:T58	
R50	Experiences Arg1:T65 Arg2:T28	
R51	Experiences Arg1:T65 Arg2:T44	
R52	Used_for Arg1:T29 Arg2:T44	
R53	Experiences Arg1:T65 Arg2:T30	
R54	Used_for Arg1:T31 Arg2:T49	
R55	Experiences Arg1:T65 Arg2:T49	
R56	Experiences Arg1:T66 Arg2:T32	
R57	Experiences Arg1:T66 Arg2:T33	
R58	Has_Duration_or_Interval Arg1:T32 Arg2:T67	
R59	Experiences Arg1:T66 Arg2:T69	
R60	Has_Duration_or_Interval Arg1:T32 Arg2:T68	
R61	Experiences Arg1:T66 Arg2:T34	
R62	Before Arg1:T32 Arg2:T35	
R63	Before Arg1:T34 Arg2:T35	
R64	Experiences Arg1:T70 Arg2:T36	
R65	Experiences Arg1:T70 Arg2:T37	
R66	Has_Duration_or_Interval Arg1:T36 Arg2:T71	
R67	Before Arg1:T36 Arg2:T38	
R68	Before Arg1:T37 Arg2:T38	
R69	Experiences Arg1:T72 Arg2:T79	
#72	AnnotatorNotes T79	C4745084; Medical Condition; Finding
R70	Experiences Arg1:T72 Arg2:T39	
T86	Quantifier_or_Qualifier 1868 1874	activa
#73	AnnotatorNotes T86	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R71	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T86	
R72	Experiences Arg1:T72 Arg2:T40	
R73	Experiences Arg1:T72 Arg2:T21	
R77	After Arg1:T42 Arg2:T45	
R78	After Arg1:T19 Arg2:T45	
#74	AnnotatorNotes T75	C1521726; partial response; Finding
R79	After Arg1:T74 Arg2:T48	
R80	After Arg1:T25 Arg2:T48	
R81	Overlap Arg1:T25 Arg2:T47	
R82	Before Arg1:T24 Arg2:T74	
R83	Causes Arg1:T29 Arg2:T30	
R84	Causes Arg1:T49 Arg2:T30	
R85	Causes Arg1:T28 Arg2:T58	
T87	Quantifier_or_Qualifier 760 766	último
R90	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T87	
R91	Overlap Arg1:T75 Arg2:T46	
R45	Overlap Arg1:T47 Arg2:T64	
R92	Has_Duration_or_Interval Arg1:T34 Arg2:T68	
T88	Observation 911 920;936 941	respuesta mejor
R96	Experiences Arg1:T59 Arg2:T88	
R97	Overlap Arg1:T88 Arg2:T46	
#75	AnnotatorNotes T87	C1517741; Last; Qualitative Concept
#76	AnnotatorNotes T88	C0221607; Favorable response to treatment; Finding (?) | C0184784; Fair therapeutic response; Finding (?)
A13	Experiencer T52 Patient
A14	Experiencer T53 Patient
A15	Experiencer T54 Patient
A16	Experiencer T55 Patient
A17	Experiencer T56 Patient
A18	Experiencer T57 Patient
A19	Experiencer T59 Patient
A20	Experiencer T60 Patient
A21	Experiencer T61 Patient
A22	Experiencer T65 Patient
A23	Experiencer T66 Patient
A24	Experiencer T70 Patient
A25	Experiencer T72 Patient
A26	Experiencer T63 Patient
